-
1 Comment
immatics biotechnologies GmbH is currently in a long term uptrend where the price is trading 11.6% above its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the sector with a price to sales ratio of 0.0.
Based on the above factors, immatics biotechnologies GmbH gets an overall score of 2/5.
Industry | |
---|---|
CurrencyCode | USD |
Exchange | NASDAQ |
ISIN | None |
Sector |
Market Cap | 673M |
---|---|
Beta | nan |
Target Price | None |
PE Ratio | None |
Dividend Yield | 0.0% |
Immatics N.V. engages in the discovery of targets for cancer immunotherapies. It is developing targeted immunotherapies with focus on treating solid tumors through two distinct therapeutic modalities, such as Adoptive Cell Therapies and antibody-like TCR Bispecifics. Its pipeline comprises of eight therapeutic programs, of which four are in clinical trials and four are in preclinical development. The company is based in Tuebingen, Germany.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for IMTXW using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2024